Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06079671 · ClinicalTrials.gov registry record · Phase 3

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

A Phase 3 study of Locally Advanced Cervical Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
800
Enrollment target
20
Study locations

NCT06079671 is a Phase 3 study of Locally Advanced Cervical Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 800 participants. The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06079671, a Phase 3 study of Locally Advanced Cervical Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
800 participants
Enrollment target
20
Study locations

Study Summary

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

Interventions

  • OTHER Placebo
  • BIOLOGICAL Volrustomig

Study Locations (20)

Georgia

  • Research Site - Atlanta
  • Research Site - Augusta
  • Research Site - Savannah

Louisiana

  • Research Site - New Orleans
  • Research Site - New Orleans
  • Research Site - Shreveport

Arizona

  • Research Site - Phoenix
  • Research Site - Tucson

California

  • Research Site - La Jolla
  • Research Site - West Hollywood

New York

  • Research Site - New York
  • Research Site - Syracuse

Ohio

  • Research Site - Cleveland
  • Research Site - Columbus

Alabama

  • Research Site - Birmingham

Arkansas

  • Research Site - Little Rock

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2023-09-22
Est. Completion 2030-09-30
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT06079671

The ClinicalTrials.gov registry entry for NCT06079671 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Locally Advanced Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06079671 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Georgia, Louisiana, Arizona.

Frequently Asked Questions

What is clinical trial NCT06079671 about?

NCT06079671 is a clinical study titled "Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)". This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

What is the current status of trial NCT06079671?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2023-09-22. Estimated completion is 2030-09-30.

What conditions does trial NCT06079671 study?

This clinical trial studies the following conditions: Locally Advanced Cervical Cancer.

What interventions are being tested in trial NCT06079671?

The interventions under investigation include: Placebo (OTHER), Volrustomig (BIOLOGICAL).

Who is sponsoring clinical trial NCT06079671?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06079671 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Locally Advanced Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.